Tata Elxsi Q1 FY27: JPMorgan Neutral at ₹3,500, Kotak Sell at ₹3,000 on Margin Concerns
Tata Elxsi posted Q1 FY27 revenue of ₹1,021.1 crore, up 14.5% YoY, but EBIT margins fell to 18.97% from 22.27% QoQ. JPMorgan maintained Neutral with a ₹3,500 target, cutting FY27–29 estimates by 1–13%, while Kotak kept a Sell rating at ₹3,000, reducing estimates by 10–14%, both citing deal transition costs, weak Auto and Healthcare segments, and persistent margin pressure.

*this image is generated using AI for illustrative purposes only.
Tata Elxsi reported Q1 revenue from operations of ₹1,021.1 crore (10.2B rupees), marking a 14.5% year-on-year increase and crossing the ₹1,000 crore milestone for the first time. On a sequential basis, revenue grew from 9.94B rupees in the prior quarter. Net profit for the quarter stood at 1.7B rupees, compared to 2.20B rupees in the previous quarter. EBIT came in at 1.94B rupees, reflecting an EBIT margin of 18.97%. The growth was driven by strong deal execution and momentum in large strategic engagements across the Transportation and Media & Communication verticals. The Board of Directors approved the audited financial results at a meeting held on July 14, 2026, with statutory auditors B S R & Co. LLP issuing an unmodified opinion confirming compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Analyst Ratings and Views
Following the Q1 FY27 results, leading institutional brokerages weighed in with their assessments, both flagging margin disappointments and earnings estimate cuts. The key ratings and target prices are summarised below:
| Broker: | Rating | Target Price | Key Concern |
|---|---|---|---|
| JPMorgan: | Neutral | ₹3,500 | Margins down 330 bps; Auto & Healthcare weak |
| Kotak Institutional Equities: | Sell | ₹3,000 | Deal transition costs; margin pressure to persist |
JPMorgan maintained its Neutral rating on Tata Elxsi with a target price of ₹3,500. The brokerage noted that Q1 FY27 revenue beat expectations, with 1.3% quarter-on-quarter constant currency growth led by the Media & Telecom segment. However, margins plunged 330 basis points due to deal transition costs, ramp-up expenses, and investment-related costs. JPMorgan flagged that the Auto and Healthcare segments remained weak, and that FY27 overall growth continues to depend on a recovery in the Healthcare business. As a result, JPMorgan cut its FY27–29 earnings estimates by 1–13%.
Kotak Institutional Equities maintained its Sell rating with a target price of ₹3,000. Kotak noted that while Q1 FY27 revenue was broadly in line with expectations, profitability disappointed due to deal transition costs and upfront go-to-market and delivery investments. The Auto and Medical Devices segments remained weak, and Kotak expects margin pressures to persist. Accordingly, Kotak reduced its FY27–29 earnings estimates by 10–14%.
Financial Performance
Profit before tax for the quarter stood at ₹232.5 crore, up 18.4% year-on-year. EBIT for the quarter was 1.94B rupees with a margin of 18.97%, compared to 2.21B rupees and a margin of 22.27% in the prior quarter. Total expenses for the quarter increased, with employee benefits expense remaining the largest cost component.
The following table summarises the key financial metrics for the quarter:
| Metric: | Q1 FY27 | Q1 FY26 (YoY) | Prior Quarter (QoQ) |
|---|---|---|---|
| Revenue from Operations: | ₹1,021.1 Cr (10.2B Rupees) | ₹892.1 Cr | 9.94B Rupees |
| EBIT: | 1.94B Rupees | — | 2.21B Rupees |
| EBIT Margin: | 18.97% | 22.27% | 22.27% |
| Profit Before Tax: | ₹232.5 Cr | ₹196.3 Cr | — |
| Net Profit: | 1.7B Rupees | — | 2.20B Rupees |
Operational Highlights
The Transportation segment reported a growth of 13.3% year-on-year, driven by accelerated OEM engagements and strategic wins in the off-road and aerospace segments. OEM revenues now constitute 78% of automotive revenues. The Media & Communications segment grew 22.2% year-on-year, supported by the ramp-up of key engagements with global operators and broadcasters. The Healthcare and Life Sciences business reported a growth of 1.7% quarter-on-quarter.
Management Guidance
Following the quarterly results, management shared its outlook across key business verticals and margins during the concall. The company's aspiration for FY27 remains a high single-digit growth rate, contingent on the healthcare business picking up. The Healthcare business is expected to see growth in the current financial year, despite Q1 FY27 being near flat due to delayed deal awards.
The following table summarises the key guidance provided by management:
| Area: | Guidance |
|---|---|
| FY27 Overall Growth: | High single-digit growth rate, contingent on healthcare recovery |
| Healthcare: | Growth expected in FY27 despite near-flat Q1 FY27 due to delayed deal awards |
| Transportation: | Projected to grow over next two to three quarters; US and APAC to offset softness in Germany |
| Media & Communication: | Expected to continue growth over next two to three quarters via deal ramp-ups and new large consolidation deals |
| EBIT Margins: | Wage hike impact to be balanced in Q2; sequential ramp-up towards Q4 as revenues pick up and hikes are absorbed |
Strategic Partnerships and Product Launches
Tata Elxsi entered into a strategic partnership with JSW Motors to establish the JNEXT – JSW NextGen Technology Centre in Pune, which will serve as a strategic engineering hub for next-generation software-defined, AI-powered mobility solutions. The company also advanced its partnership with Sky through the NEURON platform portfolio, delivering a 30% improvement in operational efficiency as part of AI-led autonomous network transformation. Additionally, Tata Elxsi launched AnaTel, an AI-native software development platform for healthcare and medical technology companies co-developed with OpenAna, and ViTel, a Material Intelligence solution for Medical Device manufacturers co-developed with Viridium AI, addressing country-of-origin compliance and material risk.
Historical Stock Returns for Tata Elxsi
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -5.05% | -5.30% | -13.71% | -36.23% | -43.18% | -19.70% |
What specific indicators will signal the anticipated recovery in the Healthcare segment during FY27?
How will the strategic partnership with JSW Motors contribute to revenue growth in the Transportation vertical over the next few quarters?
Can the sequential margin ramp-up expected by Q4 be sustained if deal transition costs remain elevated?































